Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Immunogenicity of Td-mIPV, Tdap-vIPV, Td, aP and Tdap in Adolescents and Adults
2015-005197-38Phase 2
- Sponsor
- Sanofi
- Start
- Nov 2015
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, single-arm trial of tetanus toxoid + reduced diphtheria toxoid + acellular pertussis vaccine in pertussis, sponsored by Sanofi. Primary endpoint: Seroprotection against tetanus and diphtheria before and after revaccination.
02
Drugs
tetanus toxoid + reduced diphtheria toxoid + acellular pertussis vaccine
03
Conditions
pertussis
Beyond the preview
Go deeper on 2015-005197-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-005197-38.